Abatacept and glomerular diseases: The open road for the second signal as a new target is settled down

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 9, Issue 1, 2015, Pages 2-14

  Trimarchi, Hernán ^a  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

Abatacept; B7 1; CD28; CD80; CTLA 4; Glomerulopathy; Podocyte; Proteinuria

Indexed keywords

ABATACEPT; B7 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CD28 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PROTEIN BINDING;

ARTICLE; B CELL LYMPHOMA; BACTERIAL ARTHRITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULITIS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG SAFETY; ENDOMETRIUM CANCER; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LUNG ASPERGILLOSIS; MELANOMA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SEPSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; DRUG EFFECTS; GLOMERULONEPHRITIS; IMMUNOLOGY; KIDNEY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATENT; PATHOLOGY; T LYMPHOCYTE;

ABATACEPT; ANIMALS; ANTIGENS, CD28; ANTIGENS, CD80; CTLA-4 ANTIGEN; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PROTEIN BINDING; PROTEINURIA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84930896065     PISSN: 18722148     EISSN: 22123334     Source Type: Journal    
DOI: 10.2174/1872214809666150302104542     Document Type: Article

References (163)

1. [1] United States Renal Data System Annual Data Report. United States Renal Data System [online], http://www.usrds.org/2014/view/v2_01.aspx,Volume2,Chapter1,Figure1.7.
2. [2] Cravedi P, Ruggenenti P, Remuzzi G. Proteinuria should be used as a surrogate in CKD. Nat Rev Nephrol 2012; 8(5): 301-6.
3. [3] Lattanzio MR, Weir MR. Have we fallen off target with concerns surrounding dual RAAS blockade? Kidney Int 2010; 78(6): 539-45.
4. [4] de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, A Target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65(6): 2309-20.
5. [5] de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110(8): 921-7.
6. [6] D’Amicco G, Bazzi C. Pathophysiology of proteinuria. Kidney Int 2003; 63 (3): 809-25.
7. [7] Semenenko, S.B., Bulyk, R.Y. Method for diagnosing proteinuria. UA58394 (2011).
8. [8] Hznenko, A.I., Khaminich, A.V. Method for diagnosing compensated proteinuria. UA57396 (2011).
9. [9] Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23(3): 381-99.
10. [10] Helal I, Fick-Brosnahan GM, Reed-Guitomer B, Schrier R. Glomerular hyperfiltration: Definitions, mechanisms and clinical mplications. Nat Rev Nephrol 2012; 8 (5): 293-300.
11. [11] Miyata T, van Ypersele de Strihou C. Diabetic nephropathy. A disorder of oxygen metabolism?. Nat Rev Nephrol 2010; 6 (2): 83-95.
12. [12] Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int 2004; 66 (S92): 76-89.
13. [13] Tsokos, G.C., Yuang, T.J., Chun-Shin, H. Methods for treating inflammatory immune disorders. US20140161769 (2014).
14. [14] Trimarchi H. Primary focal and segmental glomerulosclerosis and suPAR: Where do we stand and where are we heading to? World J Nephrol 2013; 2(4): 103-10.
15. [15] Yu CC. Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369(25): 2416-23.
16. [16] Salant, D.J. Diagnostics for membranous nephropathy. US2013280738 (2013).
17. [17] Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11(2): 203-10.
18. [18] Tihamer, O. CTLA4 fusion proteins for the treatment of diabetes. WO2014004847 (2014).
19. [19] Li, Q. Novel soluble CTLA4 variants. WO2013041029 (2013).
20. [20] Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4 (8): 444-52.
21. [21] Miyata T, van Ypersele de Strihou. Diabetic nephropathy: A disorder of oxygen metabolism?. Nat Rev Nephrology 2010; 6 (2): 83-95.
22. [22] Giuletti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients has a proinflammatory profile. 1, 25-Dihydroxyvitamin D(3) works as antiinflammatory. Diabetic Res Clin Pract 2007; 77 (1): 47-57
23. [23] Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis. Arthritis Rheum 2014; 66(2): 379-89.
24. [24] Wofsy D, Hillson JL, Diamond B. Abatacept for Lupus Nephritis: Alternative definitions of complete response support conflicting results. Arthritis Rheum 2012; 64(11): 3660-5.
25. [25] Haviv, A., Tarcic, N. Treatment of lupus arthritis using laquinimod. NZ602512 (2010).
26. [26] Wilmer WA, Rovin BA, Herbert CJ, Rao SV, Kumor K, Herbert LA. Management of glomerular proteinuria: A commentary. J Am Soc Nephrol 2003; 14 (12): 3127-32.
27. [27] Fellstroem, B., Haellgren, R. Method and means for treating glomerulonephritis. WO1999047144 (1999).
28. [28] Evans, M.J., Matis, L.A., Mueller, E.E., Nye, S.H., Rollins, S., Rother, R.P., Springhorn, J.P., Squinto, S.P., Thomas, T.C., Wilkins, J.A. Glomerulonephritis, antibodies at low dosage. US6355245 (2002).
29. [29] Bock, G.H. Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab. WO2009145831 (2009).
30. [30] Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, et al. CD28 mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007; 109(11): 5002-10.
31. [31] Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88 dependent signaling pathway. Nat Immunol 2002; 3 (2): 196-200.
32. [32] Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R.848. Nat Immunol 2002; 3 (6): 499.
33. [33] Ozinsky A, Underhill DM, Fontenot JD, Haijar AM, Smith KD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97 (25): 13766-71.
34. [34] Hoebe K, Jannsen EM, Ki SO, Alexopoulou L, Flavell SA, Han H, et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and doublé stranded RNA occurs by Trifdependent and Trif-independent pathways. Nat Immunol 2003; 4 (12): 1223-9.
35. [35] Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int 1998; 53(5): 1209-16.
36. [36] Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol 2012; 23(12): 1917-28.
37. [37] Beck Jr LH, Salant DJ. Membranous nephropathy: Recent travels and new roads ahead. Kidney Int 2010; 77(9): 765-70.
38. [38] Moore DF, Krokhin OV, Beavis RC, Ries M, Robinson Ch, Goldin E, Brady RO, Wilkins JA, Schiffmann R. Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities. PNAS 2007; 104(8): 2873-8.
39. [39] Reiser, J. Reducing soluble urokinase receptor in the circulation. US2014083945 (2014).
40. [40] Halloran, P., Holland, M.A. The detection of globotriaosylceramide (GL3) in human urine samples using an antibody sandwich. WO201142297 (2011).
41. [41] Glezer, E., Kenten, J., Kumar, S., Nikolenko, G. Kidney function biomarkers. US20150025004 (2015).
42. [42] Fornoni, A., Burke, G.W., Merscher-Gomez, S. Assays, methods and kits for predicting renal disease and personalized treatment strategies. CA2852904 (2012).
43. [43] Burke, G.W., Fornoni, A., Merscher-Gomez, S. Assays, methods and kits for predicting renal disease and personalized treatment strategies. WO2012054321 (2012).
44. [44] Jefferson JA, Nelson PJ, Najafian B, Shankland SJ. Podocyte Disorders: Core Curriculum 2011. Am J Kidney Dis 2011; 58(4): 666-77.
45. [45] Reiser J, Gupta V, Kistler A. Toward the development of podocytespecific drugs. Kidney Int 2010; 77(8): 662-8.
46. [46] Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285 (1): F40-8.
47. [47] Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, et al. Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16 (10): 2941-52.
48. [48] Masanori, H., Kurosawa, H., Hirayama, Y. Method for detecting podocytes in urine. WO2014104019 (2014).
49. [49] Tristan, H., Reiser, J., Gupta, V. Podocyte cultures and uses thereof. WO2014150178 (2014).
50. [50] Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17(8): 952-60.
51. [51] Clement LC, Avila-Casado C, Macé C, Soria E, Bakker WW, Kersten S, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011; 17(1): 117-122.
52. [52] Reiser, J. von Gersdorff, M. Loos, Oh J, Asanuma K, Giardino L, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2014; 113(10): 1390-7.
53. [53] Reiser J, Alachkar N. Abate or applaud abatacept in proteinuric kidney disease?. Nat Rev Nephrol 2014; 10(3): 128-30.
54. [54] Miller, M.M., Mapelli, C., Allen, M.P., Bowsher, M.S., Boy, K.M., Gillis, E.P., Langley, D.R., Mull, E., Poirier, M.A., Sanghvi, N., Sun, L.-Q., Tenney, D.J., Yeung, K.-S., Zhu, J., Reid, P.C., Scola, P.M. Macrocyclic inhibitors of the PD-1/PD-L1 and CD80 (B7-1)/PD-L1 protein/protein interactions. US2014294898 (2014).
55. [55] Robblee, J., He, X., Yin, Y., Lin, Y.Y., Collins, B., Murphy, J., Kaundinya, G.V. Methods related to CTLA4-FC fusion proteins. WO2014149067 (2014).
56. [56] Garin EH, Diaz LN, Mu W. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 2009; 20(2): 260-6.
57. [57] Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H et al. Podocyte protection by darbepoetin: Preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72(4): 455-63.
58. [58] Sekulic M, Sekulic SP. A compendium of urinary biomarkers indicative of glomerular podocytopathy. Pathol Res Int Vol 2013; Article ID 782395.
59. [59] Korhonen N, Moilonen E. Abatacept, a novel CD80/86-CD28 T cell Co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009; 104 (4): 276-84.
60. [60] Schwartz RH. Mueller DR, Jenkins MK, Quill H. Cold Spring Harbor Symp Quant Biol 1989; 54(2): 605-10.
61. [61] Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993; 11: 191-212.
62. [62] Suchard, S.J., Tamura, J.K. Pegylated domain antibodies monovalent for CD28 binding and methods of use. WO2014120916 (2013).
63. [63] Thiamer, O. CTLA4 fusion proteins for the treatment of diabetes. US2014099306 (2014).
64. [64] Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111(12): 1887-95.
65. [65] Floyd TL, Koehn BH, Kitchens WH, Robertson JM, Cheeseman JA, Stempora L, et al. Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall. J Immunol 2011; 186(4): 2033-41.
66. [66] Bingaman AW, Farber DL. Memory T cells in transplantation: Generation, function, and potential role in rejection. Am J Transplant 2004; 4(6): 846-52.
67. [67] Yamada Y, Boskovic S, Aoyama A, Murakami T, Putheti P, Smith RN, et al. Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant 2012; 12(2): 330-40.
68. [68] Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Grlbben JG, Nadler LM. B7-1 and B7-2 do not deliver identical costimulatory signals, since 87-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995; 2(5): 523-32.
69. [69] Tamir A, Eisenbraun MD, García GG, Miller RA. Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell/APC interaction. J Immunol 200; 165(3): 1243-51.
70. [70] Wulfing C, Davis MM. A receptor/ cytoskeletal movement triggered by costimulation during T cell activation. Science 1998; 282(5397): 2266-9.
71. [71] Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, et al. The immunological synapse. Annu Rev Immunol 2001; 19: 375-96.
72. [72] Shaw AS, Allen PM. Kissing cousins: immunological and neurological synapses. Nat Immunol 2001; 2(7): 575-6.
73. [73] Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological synapse: A molecular machine controlling T cell activation. Science 1999; 285(5425): 221-7.
74. [74] Acuto O, Cantrell D. T cell activation and the cytoskeleton. Annu Rev Immunol 2000; 18: 165-84.
75. [75] Welsh GI, Saleem MA. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol 2012; 8(1): 14-21.
76. [76] Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48.
77. [77] Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
78. [78] Hara, M., Kurosawa, H., Hirayama Y. Method for detecting podocytes in urine. WO2014104019 (2014).
79. [79] Hays, T., Reiser, J., Gupta, V. Podocyte cultures and uses thereof. WO2014150178 (2014).
80. [80] Adler S. Characterization of glomerular epithelial cell matrix receptors. Am J Pathol 1992; 141(3): 571-8.
81. [81] Regele HM, Fillipovic E, Langer B, Poczewki H, Kraxberger I, Bittner RE, et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J Am Soc Nephrol 2000; 11(3): 403-12.
82. [82] Raats CJ, van den Born J, Bakker MA, Oppers-Walgreen B, Pisa BJ, Dijkman HB, et al. Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies. Am J Pathol 2000; 156(5): 1749-65.
83. [83] Kreidberg JA. Functions of alpha3 beta1 integrin. Curr Opin Cell Biol 2000; 12(5): 548-53.
84. [84] Kreidberg JA, Donovan MJ, Goldstein SL, Rennke H, Shepherd K, Jones RC, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 1996; 122(11): 3537-47.
85. [85] Satoh S, Suzuki A, Asari Y, Sato M, Kojima N, Sato T, et al. Glomerular endothelium exhibits enhanced expression of costimulatory adhesion molecules, CD80 and CD86, by warm ischemia/ reperfusion injury in rats. Lab Invest 2002; 82(9): 1209-17.
86. [86] Voznesenskaja, T.J.S., Sergeeva, T.V.E., Tsygin, A.N., Bershova, T.J.V., Bakanov M.I. Diagnostic technique for nephrotic syndrome with minimal changes in children. RU2522238 (2014).
87. [87] Garin EH, Mu W, Arthur JM, Rivard CJ, Araya CE, Shimada M, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis, Kidney Int 2010; 78(3): 296-302.
88. [88] Navarro-Muñoz M, Ibernon M, Pérez V, Ara J, Espinal A, López D, et al. Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimalchange disease and focal segmental glomerulosclerosis in adult patients. Nephrol Dial Transplant, 2011; 26(12): 3914-23.
89. [89] Wang, W., Zhu, J., Zhang, X. Micro-RNA used for regulating expression of CD80 gene. CN103571837 (2014).
90. [90] Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257(5071): 792-5.
91. [91] Lenschow D, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257(5071): 789-92.
92. [92] Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265(5176): 1225-7.
93. [93] Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381(6581): 434-8.
94. [94] Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5(11): 1303-7.
95. [95] Trambley J, Bingaman AW, Lin A, Elwood ET, Waitze SY, Ha J, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104(12): 1715-22.
96. [96] Ford ML, Wagener ME, Hanna SS, Pearson TC, Kirk AD, Larsen CP. A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection. J Immunol 2008; 180(11): 7203-11.
97. [97] Ford ML, Koehn BH, Wagener ME, Jiang W, Gangappa S, Pearson TC, et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007; 204(2): 299-309.
98. [98] Ford ML, Adams AB, Pearson TC. Targeting co-stimulatory pathways: Transplantation and autoimmunity. Nat Rev Nephrol 2014; 10(1): 14-24.
99. [99] Ilg, T.S., Kool, J. Toll-like receptors and immunomodulatory oligonucleotides. AU283359 (2013).
100. [100] Gomari RP, Arranz A, Juarranz Y, Gutierrez-Cañas I, García-Gomez M, Leceta J, et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 2007; 28(9): 1825-32.
101. [101] Ishii K J, Uematsu S, Akira S. Toll gates for future immunotherapy. Curr Pharm Des 2007; 12(32): 4135-42.
102. [102] Shigeoka AA, Holscher TD, King AJ, Hall FW, Kiosses WB, Tobias PS, et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and-independent pathways. J Immunol 2007; 178(19): 6252-8.
103. [103] Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4(7): 499-511.
104. [104] Imler JL, Hoffmann JA. Toll receptors in innate immunity. Trends Cell Biol 2001; 11(7): 304-11.
105. [105] Kawai T, Akira S. TLR signaling. Cell Death Different 2006; 13(5): 816-25.
106. [106] Rousseau, F., Loyau, J. Anti-TLR4 antibodies and uses thereof. CA2869048 (2012).
107. [107] Carlton, J.M., Chen, S. Toll-like receptor 3 antagonists, methods and uses. US2014255388 (2014).
108. [108] McCall, J., Hoffman, E., Kanneboyina, N. Non-hormonal steroid modulators of NF-Kb for treatment of disease. NZ603107 (2014).
109. [109] Beg, A.A., Enkemann, S.A., Chen, D.T. Gene signatur for the prediction of NF-kappab activity. WO20130657198 (2013).
110. [110] Anders HJ, Schlöndorff H. Toll-like receptors: Emerging concepts in kidney disease. Curr Opin Nephrol Hypertens 2007; 16(3): 177-83.
111. [111] Iwasaki A, Medzhitov R. Toll_like receptor control of the adaptive immune responses. Nat Immunol 2004; 5(10): 987-95.
112. [112] Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003; 3(2): 169-76.
113. [113] Pacquement H, Sinnassamy P, Quintana E, Thomas C, Bensman A, Zucker JM. Nephrotic syndrome and B leukemia. Arch Fr Pediatr 1989; 46(10): 741-2.
114. [114] Brown HJ, Lock HR, Wolfs TG, Buurman WA, Sacks SH, Robson MG. Toll_like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2. J Am Soc Nephrol 2007; 18(6): 1732-9.
115. [115] Brown HJ, Sacks SH, Robson MG. Toll like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis. J Am Soc Nephrol 2006; 17(7): 1931-9.
116. [116] Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 2010; 6(4): 224-35.
117. [117] Shimada M, Ishimoto T, Lee PY, Lanaspa MA, Rivard CJ, Roncal-Jimenez VA. Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-ĸB-dependent pathway. Nephrol Dial Transplant 2012; 71(1): 81-9.
118. [118] Girndt M, Sester U, Kaul H, Hünger H, Köhler H. Glucocorticoids inhibit activation-dependent expression of costimulatory molecule B7-1 molecule in human monocytes. Transplantation 1998; 66(3): 370-5.
119. [119] Liu B, Yang Y, Dai J, Medzhitov R, Freudenberg MA, Zhang PL, et al. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 2006; 177(10): 6880-8.
120. [120] Ishimoto T, Shimada M, García G, Kosugi T, Sato W, Lee PY, et al. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. Nephrol Dial Transplant 2013; 28(6): 1439-46.
121. [121] Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322(5899): 271-5.
122. [122] Araya C, Diaz L, Wasserfall C, Atkinson M, Mu W, Johnson R, et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 2009; 24(9): 1691-8.
123. [123] Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, et al. Viral souble_stranded RNA aggravates lupus nephritis through Toll_like receptor 3 on glomerular mesangial cells and antigen presenting cells. J Am Soc Nephrol 2005; 16(5): 1326-38.
124. [124] Pawar RD, Patole PS, Zecher D, Segerer S, Kretzler M, Schlöndorff D, et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2006; 17(1): 141-9.
125. [125] Wörnle M, Schmid H, Banas B, Merkle M, Henger A, Roeder M, et al. Novel role of Toll_like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006; 168(2): 370-85.
126. [126] Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. Nat Rev Nephrol 2011 (4); 6: 224-35.
127. [127] Brown HJ, Sacks SH, Robson MG. Toll-like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis. J Am Soc Nephrol 2006; 17 (7): 1931-9.
128. [128] Brown HJ, Lock HR, Wolfs TG, Buurman WA, Sacks SH, Robson MG. Toll like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibodymediated glomerulonephritis via CXCL1 and CXCL2. J Am Soc Nephrol 2007; 18 (6): 1732-9.
129. [129] Robblee, J., He, X., Yin, Y., Lin, Y., Collins, Murphy J., Kaundinya, G.V. Methods related to CTLA4-FC fusion proteins. WO2014149067 (2014).
130. [130] Malissen, B., Malissen, M. Methods for screening drugs for reducing CD28 costimulation of T cells. WO2014173840 (2014).
131. [131] Suchard, S., Tamura, J. Pegylated domain antibodies monovalent for CD28 binding and methods of use. WO2014120916 (2014).
132. [132] Park, S.H., Cho, M.L. Immunotherapeuthic of nansome form comprising cell suspension and abatacept. KR20130015337 (2013).
133. [133] Nabil, H. Anti-CD40L, anti-B7.1 (CD80), anti-B7.2 (CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. US20020058029 (2002).
134. [134] Hale, B.M., Ptacek, J., Nolan, G.P. Methods for autoimmune disease diagnosis, prognosis, and treatment. WO2011106558 (2011).
135. [135] Lieping, C. B7-DC variants. US8039589 (2011).
136. [136] Linsley, P.S., Ledbetter, J.A., Nittin, K.D., Brady, W. CTLA4 receptor and uses thereof. US5885796 (1999).
137. [137] Queva, C. Targeted binding agents against B7-H1. CA2778714 (2011).
138. [138] Anderson, D., Marken, J. Human B7 polypeptide B7-H3A. US20060154313 (2006).
139. [139] Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation B7 antigen. J Exp Med 1991: 174(3): 561-9.
140. [140] Ling-Ling, A., Fung, M.S., Wu, H. Agents that activate or inhibit toll-like receptor 9. WO200303569 (2003).
141. [141] Yin, H., Watkins, L.R. Toll-like receptor modulators and uses thereof. US8642614 (2014).
142. [142] Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86(3): 557-66.
143. [143] Fagerhol, M. Competitive S10049 immune assays. US227725 (2014).
144. [144] Rastaldi MP, Ferrario F, Crippa A, Dell’Antonio G, Casartelli G, Grillo C, et al. Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis. J Am Soc Nephrol 2000; 11(11): 2036-43.
145. [145] Frosch M, Vogl T, Waldherr R, Sorg C, Sunderkötter C, Roth J. Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis. J Leukocyte Biol 2004; 75(2): 198-206.
146. [146] Haraldsson B. A New era of podocyte-targeted therapy for proteinuric kidney disease. N Engl J Med 2013; 369(25): 2453-4.
147. Becker JU, Schiffer M, Bockmeyer CL. Detection of glomerular CD80 (B7-1) mRNA by qRT-PCR and on podocytes by immunostains on paraffin embedded biopsies with FSGS. 10th International Podocyte Conference, Freiburg June 2014. Nephron Clin Pract 2014; 126: A IV7.
148. [148] Michel M, Henri P, Vincent FB, Leon N, Marcelli C. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine 2013; 80(6): 660-3.
149. [149] Wu Q, Jinde K, Endoh M, Sakai H. Costimulatory molecules CD80 and CD86 in human crescentic glomerulonephritis. Am J Kidney Dis 2003; 41(5): 950-61.
150. [150] Mondino A, Jenkins MK: Surface proteins involved in T cell costimulation. J Leukoc Biol 1994; 55(6): 805-15.
151. [151] Daikh D, Wofsy D, Imboden JB. The CD28-B7 costimulatory pathway and its role in autoimmune disease. J Leukoc Biol 1997; 62(2): 156-62.
152. [152] Wu Q, Jinde K, Endoh M, Sakai H. Clinical significance of costimulatory molecules CD80/CD86 expression in IgA nephropathy. Kidney Int 2004; 65(3): 888-96.
153. [153] Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46 (6): 1470-9.
154. [154] Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349 (20): 1907-15.
155. [155] Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 2006; 144 (12): 865-76.
156. [156] Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58 (4): 953-63.
157. Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNF_) Agents. (NURTURE 1) Available at: https://clinicaltrials.gov/ctz/results?term=abatacept&pg=1 (Accessed on: February 20th, 2015).
158. Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Available at: https://clinicaltrials.gov/ct2/show/NCT01714817?term =abatacept&rank=45NCT01714817 (Accessed on: February 20th, 2015).
159. [159] Song B, Smink AM, Jones CJ, Callaghan JM, Firth SD, Bernard CA, et al. The directed differentiation of human iPS into kidney podocytes. PLoS ONE 2012; 7(9): e46453.
160. [160] Mae SI, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, et al. Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat Commun 2013; 4: 1367.
161. [161] Buensuceso, C. Induced pluripotent stem cells prepared from human kidney-derived cells. WO201309591 (2012).
162. [162] Kahn, M., Hasegawa, K., Teo, J.L., McMillan, M., Yasuda, S. Method for formation of induced pluripotent stem cells. WO2011019957 (2011).
163. [163] Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, et al. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 2009; 20 (5): 1041-52.